Campbell Deegan Wealth Management LLC Acquires New Position in Johnson & Johnson (NYSE:JNJ)

Campbell Deegan Wealth Management LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 3,653 shares of the company's stock, valued at approximately $528,000. Johnson & Johnson makes up about 0.6% of Campbell Deegan Wealth Management LLC's holdings, making the stock its 19th largest position.

A number of other large investors have also recently made changes to their positions in the stock. MRP Capital Investments LLC lifted its holdings in Johnson & Johnson by 4.1% during the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after purchasing an additional 65 shares during the last quarter. Syverson Strege & Co increased its stake in Johnson & Johnson by 4.9% during the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after acquiring an additional 65 shares during the period. Werba Rubin Papier Wealth Management increased its stake in Johnson & Johnson by 3.3% during the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after acquiring an additional 66 shares during the period. Denali Advisors LLC increased its stake in Johnson & Johnson by 1.3% during the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock worth $742,000 after acquiring an additional 67 shares during the period. Finally, Sage Mountain Advisors LLC increased its stake in shares of Johnson & Johnson by 0.5% in the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock valued at $2,106,000 after purchasing an additional 67 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent research reports. Royal Bank of Canada reissued an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 16th. Barclays cut their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Morgan Stanley lifted their target price on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Finally, Bank of America cut their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Price Performance

NYSE JNJ traded up $1.41 on Friday, reaching $154.99. 15,529,047 shares of the company's stock traded hands, compared to its average volume of 7,975,430. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a 50-day simple moving average of $154.31 and a 200 day simple moving average of $153.65. The stock has a market cap of $372.92 billion, a PE ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.36%. The ex-dividend date is Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.